CN105903056A - Medical composite alginate dressing containing analgesic drug and preparation method thereof - Google Patents
Medical composite alginate dressing containing analgesic drug and preparation method thereof Download PDFInfo
- Publication number
- CN105903056A CN105903056A CN201610389996.9A CN201610389996A CN105903056A CN 105903056 A CN105903056 A CN 105903056A CN 201610389996 A CN201610389996 A CN 201610389996A CN 105903056 A CN105903056 A CN 105903056A
- Authority
- CN
- China
- Prior art keywords
- alginate
- dressing
- compounding sea
- analgesic
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 157
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 157
- 229940072056 alginate Drugs 0.000 title claims abstract description 143
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title claims abstract description 142
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 229940035676 analgesics Drugs 0.000 title abstract 4
- 239000000730 antalgic agent Substances 0.000 title abstract 4
- 239000002131 composite material Substances 0.000 title 1
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 64
- 206010052428 Wound Diseases 0.000 claims abstract description 61
- 210000000416 exudates and transudate Anatomy 0.000 claims abstract description 20
- 239000004094 surface-active agent Substances 0.000 claims abstract description 17
- 238000013329 compounding Methods 0.000 claims description 79
- 230000000202 analgesic effect Effects 0.000 claims description 67
- 150000003839 salts Chemical class 0.000 claims description 34
- 239000000835 fiber Substances 0.000 claims description 32
- 239000003002 pH adjusting agent Substances 0.000 claims description 15
- 238000009987 spinning Methods 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 13
- 230000003204 osmotic effect Effects 0.000 claims description 13
- 235000010410 calcium alginate Nutrition 0.000 claims description 12
- 239000000648 calcium alginate Substances 0.000 claims description 12
- 229960002681 calcium alginate Drugs 0.000 claims description 12
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 238000001467 acupuncture Methods 0.000 claims description 10
- 229960004194 lidocaine Drugs 0.000 claims description 10
- -1 Polyethylene Polymers 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000000783 alginic acid Substances 0.000 claims description 9
- 229960001126 alginic acid Drugs 0.000 claims description 9
- 150000004781 alginic acids Chemical class 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 7
- 239000004327 boric acid Substances 0.000 claims description 7
- 235000010338 boric acid Nutrition 0.000 claims description 7
- 229960001549 ropivacaine Drugs 0.000 claims description 7
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 6
- 229960003150 bupivacaine Drugs 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 5
- 229930182566 Gentamicin Natural products 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 5
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 5
- 229960001807 prilocaine Drugs 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 229910021538 borax Inorganic materials 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 239000004328 sodium tetraborate Substances 0.000 claims description 4
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 4
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229930193140 Neomycin Natural products 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 229960000318 kanamycin Drugs 0.000 claims description 3
- 229930027917 kanamycin Natural products 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 229930182823 kanamycin A Natural products 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 229960003128 mupirocin Drugs 0.000 claims description 3
- 229930187697 mupirocin Natural products 0.000 claims description 3
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims description 3
- 229960004927 neomycin Drugs 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 239000001117 sulphuric acid Substances 0.000 claims description 3
- 235000011149 sulphuric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000036407 pain Effects 0.000 abstract description 22
- 230000029663 wound healing Effects 0.000 abstract description 13
- 230000035876 healing Effects 0.000 abstract description 8
- 238000011049 filling Methods 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 3
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- 230000036592 analgesia Effects 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000004745 nonwoven fabric Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 5
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000003589 local anesthetic agent Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- RNMDNPCBIKJCQP-UHFFFAOYSA-N 5-nonyl-7-oxabicyclo[4.1.0]hepta-1,3,5-trien-2-ol Chemical compound C(CCCCCCCC)C1=C2C(=C(C=C1)O)O2 RNMDNPCBIKJCQP-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 229960001050 bupivacaine hydrochloride Drugs 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- JCQBWMAWTUBARI-UHFFFAOYSA-N tert-butyl 3-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C=C)C1 JCQBWMAWTUBARI-UHFFFAOYSA-N 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F9/00—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
- D01F9/04—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments of alginates
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/44—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties the fleeces or layers being consolidated by mechanical means, e.g. by rolling
- D04H1/46—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties the fleeces or layers being consolidated by mechanical means, e.g. by rolling by needling or like operations to cause entanglement of fibres
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/44—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties the fleeces or layers being consolidated by mechanical means, e.g. by rolling
- D04H1/46—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties the fleeces or layers being consolidated by mechanical means, e.g. by rolling by needling or like operations to cause entanglement of fibres
- D04H1/492—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties the fleeces or layers being consolidated by mechanical means, e.g. by rolling by needling or like operations to cause entanglement of fibres by fluid jet
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06B—TREATING TEXTILE MATERIALS USING LIQUIDS, GASES OR VAPOURS
- D06B1/00—Applying liquids, gases or vapours onto textile materials to effect treatment, e.g. washing, dyeing, bleaching, sizing or impregnating
- D06B1/02—Applying liquids, gases or vapours onto textile materials to effect treatment, e.g. washing, dyeing, bleaching, sizing or impregnating by spraying or projecting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Mechanical Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medical composition alginate dressing containing analgesic drug and a preparation method thereof. The medical composition alginate dressing is prepared from, by weight, 50-99.9 parts of alginate, 0.1-25 parts of analgesic drug and 0.01-15 parts of surfactant. Compared with the prior art, the prepared medical composition alginate dressing containing the analgesic drug can be used for the surface of a wound with tissue defects and can be used for filling and supporting defected tissue, absorbing wound exudate and controlling bleeding in an assisted mode so as to promote wound healing and relieve the pain. The dressing which effectively absorbs wound exudate, provides a wet healing environment for the wound, fills and supports the defected tissue, promotes wound healing and relieves the pain of a patient is provided for the injured patient, and is suitable for being popularized in a large range.
Description
Technical field
The present invention relates to the technical field of wound dressing, more particularly, relate to a kind of medical compounding sea alginate dressing containing analgesic and preparation method thereof.
Background technology
The skin of human body and mucosa are the barriers maintaining human internal environment stable and stoping microorganism to invade, the skin caused due to reasons such as ulcer, wound, burn and inflammation and mucosa injury, the a series of problem of body can be caused, such as antibacterial infects, metabolism aggravation, moisture and protein excessively runs off, endocrine and immune system dysfunction etc., serious possible threat to life.Suitable dressing should be selected when skin and mucosa injury to cover on wound, and it can play holding wound moist environment, absorption secretions, eases pain and control hemorrhage effect, thus promotes wound healing.
The use of dressing is the important means maintaining the good healing environment of wound.Traditional dressing mainly plays isolation and bacteriostasis for wound, but frequently results in wound and be dried, destroy the somatomedin of health and easily stick on cambium, can cause the secondary insult of wound when dressing is removed.Along with people's living standard and the raising of medical level, people have higher requirement for dressing:
(1) can control and absorb exudate, keep wound moist and without the environment of transudate；
(2) bacteria preventers can be provided, build the good environment of an applicable tissue growth, promote tissue growth；
(3) there is the suitable transmitance of gas and steam；
(4) easy to use, adhesion is suitable, does not cause secondary injury；
(5) nontoxic, harmless, non-stimulated.
Alginate dressing, after coming into the market the nineties, is just constantly subjected to the welcome of patient and is increasingly becoming one of more major product of wound dressing of nursing transudate, and its market capacity increases year by year, one of main body dressing becoming wettability wound dressing.Meet above-mentioned requirements therefore, it is necessary to provide a kind of and there is the alginate dressing improving performance.
Summary of the invention
In order to solve the various problems that dressing in prior art exists, it is an object of the invention to provide a kind of can be used for the wound surface of tissue defect, filling supports defective tissue, absorbing wound exudate, assist control are hemorrhage thus promotes medical compounding sea alginate dressing containing analgesic of wound healing the sense that eases the pain and preparation method thereof.
An aspect of of the present present invention provides a kind of medical compounding sea alginate dressing containing analgesic, in parts by weight, described medical compounding sea alginate dressing includes following components: 50～99.9 parts of alginates, 0.1～25 part of analgesic and 0.01～15 part of surfactant.
One embodiment of the medical compounding sea alginate dressing containing analgesic according to the present invention, described medical compounding sea alginate dressing includes following components: 80～99 parts of alginates, 0.5～7 part of analgesic and 0.1～2.5 part of surfactant.
One embodiment of the medical compounding sea alginate dressing containing analgesic according to the present invention, described medical compounding sea alginate dressing also includes pH adjusting agent and the osmotic pressure regulator of 0.1～10 part, wherein, the usage amount of described pH adjusting agent is that the pH value that can adjust described medical compounding sea alginate dressing is to 6～11.
One embodiment of the medical compounding sea alginate dressing containing analgesic according to the present invention, described alginate is the salt formed by alginic acid and metal ion, wherein, described alginate one in sodium alginate, calcium alginate, alginic acid zinc, copper alginate, ferric alginate and alginic acid magnesium；The molecular weight of described alginate is 5000～500000, preferably 10000～300000.
One embodiment of the medical compounding sea alginate dressing containing analgesic according to the present invention, described analgesic is selected from least one in lignocaine or its salt, prilocaine or its salt, bupivacaine or its salt and ropivacaine or its salt.
One embodiment of the medical compounding sea alginate dressing containing analgesic according to the present invention, described medical compounding sea alginate dressing also includes 0～10 part of antibacterials, wherein, at least one in gentamycin or its salt, neomycin or its salt, kanamycin or its salt and mupirocin of described antibacterials.
One embodiment of the medical compounding sea alginate dressing containing analgesic according to the present invention, at least one in tween, Myrij, Brij, sodium lauryl sulphate, dodecyl sodium sulfate, poloxamer, lecithin, Polyethylene Glycol-15-hydroxy stearic acid ester, Polyethylene Glycol and polyoxyethylene nonylphenol ether of described surfactant；Described pH adjusting agent is acid or alkali, wherein, at least one in hydrochloric acid, acetic acid, sulphuric acid, boric acid, lactic acid, citric acid, tartaric acid and malic acid of acid, at least one in sodium hydroxide, sodium citrate and triethanolamine of alkali；At least one in sodium chloride, boric acid and Borax of described osmotic pressure regulator.
One embodiment of the medical compounding sea alginate dressing containing analgesic according to the present invention, the type of service of described medical compounding sea alginate dressing is lamellar or strip, and described medical compounding sea alginate dressing is applicable to acute wound, chronic wound and has the wound of transudate.
Another aspect provides the preparation method of the above-mentioned medical compounding sea alginate dressing containing analgesic, described medical compounding sea alginate dressing is to be prepared by any one mode following:
(1) by alginate fiber shredding, combing and reinforce obtain dressing with or without carrying out acupuncture or spun lacing after cross lapping again；
In described dressing, spray into the solution containing analgesic with nanometer or micron droplet mode or outstanding mixed liquid prepares described medical compounding sea alginate dressing；
(2) by the spinning solution throwing of alginate, silk is infiltrated in drawing-off and cleaning are placed on the solution containing analgesic or outstanding mixed liquid, is dried afterwards, winds and cut into alginate fiber；
By described alginate fiber shredding, combing and reinforce prepare described medical compounding sea alginate dressing with or without carrying out acupuncture or spun lacing after cross lapping again；
(3) analgesic is added in the spinning solution of alginate and by gained spinning solution throwing, by silk through drawing-off, clean, be dried, wind and cut into alginate fiber；
By described alginate fiber shredding, combing and reinforce prepare described medical compounding sea alginate dressing with or without carrying out acupuncture or spun lacing after cross lapping again.
One embodiment of the preparation method of the medical compounding sea alginate dressing containing analgesic according to the present invention, in mode (1) and mode (2), described solution containing analgesic or outstanding mixed liquid also include surfactant and, pH adjusting agent and/or osmotic pressure regulator；In mode (3), described spinning solution also includes surfactant and, pH adjusting agent and/or osmotic pressure regulator.
One embodiment of the preparation method of the medical compounding sea alginate dressing containing analgesic according to the present invention, a length of the 38 of described alginate fiber～60mm, fineness is 1.33～3.33dtex and fibre strength is 1.0～2.5cN/dtex；The weight per unit area of described medical compounding sea alginate dressing is 50～300g/m2, preferably 100～200g/m2。
Compared with prior art, the medical compounding sea alginate dressing containing analgesic that the present invention prepares can be used for the wound surface of tissue defect, filling supports defective tissue, absorb transudate, assist control is hemorrhage thus promotes wound healing and alleviates They hurt pain.The present invention provides a kind of effective absorbing wound exudate, offer wound healing wet environment, filling support defective tissue for trauma patient, promotes wound healing and alleviate the dressing of patient pain, suitable for large-scale promotion.
Detailed description of the invention
All features disclosed in this specification, or disclosed all methods or during step, in addition to mutually exclusive feature and/or step, all can combine by any way.
Any feature disclosed in this specification, unless specifically stated otherwise, all can be by other equivalences or there is the alternative features of similar purpose replaced.I.e., unless specifically stated otherwise, an example during each feature is a series of equivalence or similar characteristics.
Below medical compounding sea alginate dressing that the present invention contains analgesic and preparation method thereof is described in detail.
According to the exemplary embodiment of the present invention, in parts by weight, described medical compounding sea alginate dressing includes following components: 50～99.9 parts of alginates, 0.1～25 part of analgesic and 0.01～15 part of surfactant.Preferably, described medical compounding sea alginate dressing includes following components: 80～99 parts of alginates, 0.5～7 part of analgesic and 0.1～2.5 part of surfactant.
Specifically, alginate of the present invention is the salt formed by alginic acid and metal ion, wherein, and alginate one in sodium alginate, calcium alginate, alginic acid zinc, copper alginate, ferric alginate and alginic acid magnesium.
Alginate dressing has several big advantage: 1) when the main body of alginate dressing is calcium alginate, and dressing can provide calcium ion to wound, and the existence energy accelerating wound healing of calcium ion；2) alginate fiber has the biggest absorbing liquid ability of immigrants, the liquid of general absorbable deadweight 10～20 times；3) gel can be formed after contact wound exudate, thus provide a moist environment, accelerating wound healing to wound healing；4) alginate fiber material has good biocompatibility.
But, simple alginate dressing effect in terms of analgesia pain relieving has much room for improvement, in order to adapt to patient's requirement for wound energy quickly easing pain, the present invention creatively adds the analgesic with obvious analgesic activity to realize this purpose in alginate.
Namely, the present invention acts on also with alginate dressing moisture absorption, moisturizing, barrier and promotion wound healing etc., it is contemplated that acute wound early stage and pain chronic wound are all with long-time pain, the present invention adds analgesic on the basis of alginate dressing, to increase the analgesic effect of dressing and to improve patient and use the compliance of dressing.
According to the present invention, this analgesic is added in alginate dressing to realize the effect of pain relieving and to make up alginate dressing deficiency in terms of pain relieving simultaneously.Wherein, described analgesic is selected from least one in lignocaine or its salt, prilocaine or its salt, bupivacaine or its salt and ropivacaine or its salt, preferably lignocaine or its salt.More preferably, described medical compounding sea alginate dressing can also include 0～10 part of antibacterials, wherein, at least one in gentamycin or its salt, neomycin or its salt, kanamycin or its salt and mupirocin of antibacterials, preferably gentamycin or its salt.
Wherein, lignocaine or its salt are currently used widest local anesthetics, can be used for the surgical anesthesias such as topical anesthesia, infiltration anesthesia, peridural anesthesia.Lignocaine is local anesthetics of amide derivatives, has the most excited and suppression biphasic effect after being absorbed by organisms.In the wound and wound surface application such as burn, lignocaine can significantly reduce the pain of patient.
Prilocaine local anesthetic action is similar with lignocaine, but action time is longer, and toxicity is relatively low, accumulative the least.Bupivacaine or its salt, ropivacaine or its salt are all novel long-acting amide-type local anesthetics, have anesthesia duration long, and toxicity is low, to features such as nervus motorius retarding degree are light, thus are widely used in various operation and Postoperative Analgesia After.Apply bupivacaine or its salt can significantly reduce the pain in patient's agglutination, the inflammation of suppression wound location and stress in the wound and wound surfaces such as burn.
The medical compounding sea alginate dressing of the present invention adds lignocaine or its salt, prilocaine or its salt, bupivacaine or its salt, ropivacaine or its salt, the effect of pain relieving can be reached while absorbing wound exudate, promotion wound healing.
In sum, above-mentioned analgesic has prominent advantage for analgesia and pain relieving, therefore analgesic is joined in alginate dressing by the present invention, it is intended to combine advantage and the analgesic activity of analgesic of the physical actions such as alginate dressing moisture absorption, moisturizing, barrier and tissue augmentation, is the dressing of a kind of function admirable.
In addition to above two key component, the medical compounding sea alginate dressing of the present invention also includes surfactant, its effect is that surfactant can reduce the surface tension absorbing sepage in external dressing, strengthen the wettability of solid-liquid system, analgesic composition is played transdermal facilitation.Wherein, at least one during surfactant can be selected from tween, Myrij, Brij, sodium lauryl sulphate, dodecyl sodium sulfate, poloxamer, lecithin, Polyethylene Glycol-15-hydroxy stearic acid ester, Polyethylene Glycol and polyoxyethylene nonylphenol ether.
In addition, the medical compounding sea alginate dressing of the present invention can also include pH adjusting agent and osmotic pressure regulator, wherein, the usage amount of pH adjusting agent be the pH value that can adjust medical compounding sea alginate dressing to 6～11, thus zest when reducing dressing and Wound contact.Wherein, pH adjusting agent can be acid or alkali, and acid can be selected from least one in hydrochloric acid, acetic acid, sulphuric acid, boric acid, lactic acid, citric acid, tartaric acid and malic acid, and alkali can be selected from least one in sodium hydroxide, sodium citrate and triethanolamine；Osmotic pressure regulator can be selected from least one in sodium chloride, boric acid and Borax, and its effect is that the osmotic pressure after regulation dressing absorbing wound exudate is maintained at isotonic or slightly higher oozing.
According to the present invention, the molecular weight of the alginate in described medical compounding sea alginate dressing is 5000～500000, preferably 10000～300000.It is true that when preparing described medical compounding sea alginate dressing, alginate fiber can be directly utilized and prepares.
Specifically, the medical compounding sea alginate dressing of the present invention can be prepared by any one mode following:
(1) by alginate fiber shredding, combing and reinforce obtain dressing with or without carrying out acupuncture or spun lacing after cross lapping again；
In described dressing, spray into the solution containing analgesic with nanometer or micron droplet mode or outstanding mixed liquid prepares described medical compounding sea alginate dressing；
Using which to prepare medical compounding sea alginate dressing, technical process is simple, and course of industrialization feasibility is preferable, and analgesic is distributed mainly on dressing surface, and drug releasing rate is fast, can arrive optimal analgesic effect after Clinical practice within the shortest time.
(2) by the spinning solution throwing of alginate, silk is infiltrated in drawing-off and cleaning are placed on the solution containing analgesic or outstanding mixed liquid, is dried afterwards, winds and cut into alginate fiber；
By described alginate fiber shredding, combing and reinforce prepare described medical compounding sea alginate dressing with or without carrying out acupuncture or spun lacing after cross lapping again；
Which is used to prepare medical compounding sea alginate dressing, it is preferred that emphasis is preparing pastille alginate fiber, feature predominantly analgesic is uniformly distributed in fibrous outer surfaces.Therefore obtained dressing surface and internal analgesic distribution are the most more uniform, and the content uniformity of dressing Chinese medicine is easily controlled, and the controllability of product quality is preferable；During Clinical practice, no matter wound exudate is many or few, and medicine all can sustained release.
(3) analgesic is added in the spinning solution of alginate and by gained spinning solution throwing, by silk through drawing-off, clean, be dried, wind and cut into alginate fiber；
By described alginate fiber shredding, combing and reinforce prepare described medical compounding sea alginate dressing with or without carrying out acupuncture or spun lacing after cross lapping again.
Which is used to prepare medical compounding sea alginate dressing, it is preferred that emphasis is preparing pastille alginate fiber, feature predominantly analgesic is uniformly distributed in fibrous inside.Analgesic and alginate co-spun yarn, the manufacture difficulty containing drug fiber is slightly larger.Analgesic is all evenly distributed at dressing surface and inside, and the content uniformity of dressing Chinese medicine is easily controlled, and the controllability of product quality is preferable；In fiber-needle punched non-woven fabrics production process, contained drug will not lose medicine because of shredding, combing, lapping and acupuncture course；Some kind in described analgesic, example hydrochloric acid lignocaine, water solublity is relatively strong, can accelerate the formation of sepage infiltration rate and alginate；During Clinical practice, no matter wound exudate is many or few, and medicine all can sustained release.
Certainly, above-mentioned purified water or ethanol water can be utilized to prepare containing analgesic solution or outstanding mixed liquid.Further, in mode (1) and mode (2), above-mentioned solution containing analgesic or outstanding mixed liquid can also include surfactant and, pH adjusting agent and/or osmotic pressure regulator；In mode (3), spinning solution also can also include surfactant and, pH adjusting agent and/or osmotic pressure regulator.
According to the present invention, a length of the 38 of above-mentioned alginate fiber～60mm, fineness is 1.33～3.33dtex and fibre strength is 1.0～2.5cN/dtex.Further, the weight per unit area of obtained medical compounding sea alginate dressing is 50～300g/m2, preferably 100～200g/m2。
In use, the type of service of above-mentioned medical compounding sea alginate dressing is preferably lamellar or strip, convenient use.And, the medical compounding sea alginate dressing of the present invention is applicable to acute wound (all kinds of operative incisions, little debridement surgical, little skin injury and wiping are dampened), chronic wound (decubital ulcer, vascular lesions ulcer, osteomyelitis, tophus ulceration etc.) and has the wound of transudate, can not only absorbing wound exudate, the wet environment needed for wound healing is provided, filling tissue, assist control are hemorrhage and alleviate wound pain, and gel can be quickly formed after adhesion wound and absorbing wound exudate, there is stronger performance of keeping humidity.
It should be understood that; above-mentioned embodiment and the example below that the present invention describes in detail are merely to illustrate the present invention rather than limit the scope of the present invention, and some nonessential improvement and adjustment that those skilled in the art makes according to the foregoing of the present invention belong to protection scope of the present invention.The parameter etc. that following example is concrete is the most only that an example in OK range, i.e. those skilled in the art can be selected in the range of being done suitably by explanation herein, and does not really wants to be defined in the concrete numerical value of hereafter example.
Below in conjunction with embodiment, the medical compounding sea alginate dressing containing analgesic of the present invention is described further.
Embodiment 1:
Prescription:
Preparation method is:
(1) by non-woven fabrics needling process, the calcium alginate fibre of recipe quantity being prepared dressing, the weight per unit area of dressing is about 150g/m2；
(2) add the glacial acetic acid of recipe quantity after the lidocaine hydrochloride of recipe quantity, gentamycin, sodium chloride, polysorbas20 being dissolved in appropriate purified water, after stirring, gained solution is uniformly sprayed at nanometer or micron droplet mode the surface of above-mentioned dressing；
(3) (2) gained dressing is placed in ventilating drying equipment drying；
(4) dressing scissors after drying are cut into suitable size, encapsulate sterilizing, obtain described medical compounding sea alginate dressing.
Prepared medical compounding sea alginate dressing can absorb wound fluid, provides moistening healing environment for wound and plays the effect of analgesia pain relieving.During use, dressing is covered in affected part, the secondary dressing such as binder can be aided with.
Embodiment 2:
Prescription:
Preparation method is:
(1) by non-woven fabrics needling process, the calcium alginate fibre of recipe quantity being prepared dressing, the weight per unit area of dressing is about 200g/m2；
(2) by recipe quantity lidocaine hydrochloride, Polyethylene Glycol-15-hydroxy stearic acid ester, hydrochloric acid, Borax purified water dissolve obtained solution, solution is uniformly sprayed at nanometer or micron droplet mode the surface of above-mentioned dressing；
(3) dressing that step (2) prepares is placed in ventilating drying equipment drying；
(4) dressing scissors after drying are cut into suitable size, encapsulate sterilizing, obtain described medical compounding sea alginate dressing.
Prepared medical compounding sea alginate dressing can absorb wound fluid, provides moistening healing environment for wound and plays the effect of analgesia pain relieving.During use, dressing is covered in affected part, the secondary dressing such as binder can be aided with.
Embodiment 3:
Prescription:
Calcium alginate 93 parts
Lidocaine hydrochloride 5 parts
Tween 80 2 parts
Preparation method is:
(1) lidocaine hydrochloride of recipe quantity, Tween 80 are dissolved in appropriate purified water；
(2), after the calcium alginate fibre of suitable length and fineness being soaked 30-60 minute in the solution that step (1) prepares, dry；
(3) preparing dressing by non-woven fabrics needling process, the weight per unit area of dressing is about 170g/m2；
(4) dressing scissors are cut into suitable size, encapsulate sterilizing, obtain described medical compounding sea alginate dressing.
Prepared medical compounding sea alginate dressing can absorb wound fluid, provides moistening healing environment for wound and plays the effect of analgesia pain relieving.During use, dressing is covered in affected part, the secondary dressing such as binder can be aided with.
Embodiment 4:
Prescription:
Preparation method is:
(1) sodium alginate of recipe quantity, lidocaine hydrochloride, PLURONICS F87, Macrogol 4000, boric acid are dissolved in water, agitation and filtration. obtain spinning solution after vacuum deaerator and spinning solution is entered coagulating bath by shower nozzle extruding spray webbing, coagulating bath contains the calcium chloride solution of 10%, through drawing-off, clean, be dried and shear after curling, obtain calcium alginate fibre；
(2) preparing dressing by non-woven fabrics needling process, the weight per unit area of dressing is about 170g/m2。
(3) dressing scissors are cut into suitable size, encapsulate sterilizing, to obtain final product.
Prepared medical compounding sea alginate dressing can absorb wound fluid, provides moistening healing environment for wound and plays the effect of analgesia pain relieving.During use, dressing is covered in affected part, the secondary dressing such as binder can be aided with.
Embodiment 5
Prescription:
Preparation method is:
(1) by non-woven fabrics needling process, the calcium alginate fibre of recipe quantity being prepared dressing, the weight per unit area of dressing is about 150g/m2；
(2) add the glacial acetic acid of recipe quantity after the bupivacaine hydrochloride of recipe quantity, sodium chloride, polysorbas20 being dissolved in appropriate purified water, after stirring, gained solution is uniformly sprayed at nanometer or micron droplet mode the surface of above-mentioned dressing；
(3) (2) gained dressing is placed in ventilating drying equipment drying；
(4) dressing scissors after drying are cut into suitable size, encapsulate sterilizing, obtain described medical compounding sea alginate dressing.
Prepared medical compounding sea alginate dressing can absorb wound fluid, provides moistening healing environment for wound and plays the effect of analgesia pain relieving.During use, dressing is covered in affected part, the secondary dressing such as binder can be aided with.
Embodiment 6:
Prescription:
Calcium alginate 95 parts
Ropivacaine HCL 3 parts
Tween 80 2 parts
Preparation method is:
(1) Ropivacaine HCL of recipe quantity, Tween 80 are dissolved in appropriate purified water；
(2), after the calcium alginate fibre of suitable length and fineness being soaked 30-60 minute in the solution that step (1) prepares, dry；
(3) preparing dressing by non-woven fabrics needling process, the weight per unit area of dressing is about 170g/m2；
(4) dressing scissors are cut into suitable size, encapsulate sterilizing, obtain described medical compounding sea alginate dressing.
Prepared medical compounding sea alginate dressing can absorb wound fluid, provides moistening healing environment for wound and plays the effect of analgesia pain relieving.During use, dressing is covered in affected part, the secondary dressing such as binder can be aided with.
In sum, present invention have the advantage that
There is high-hygroscopicity, after the wound surface moderates such as the burn transudate to severe, and absorption transudate can be absorbed, gel can be formed, for still keeping overall structure after the heal wet environment providing good, and use of wound；There is biocompatibility well, to wound nonirritant, avirulence after formation gel；There is good analgesic activity, the compliance of patient can be increased and reduce medical expense；The preparation technology of the present invention is simple, beneficially industrialized great production.
The invention is not limited in aforesaid detailed description of the invention.The present invention expands to any new feature disclosed in this manual or any new combination, and the arbitrary new method that discloses or the step of process or any new combination.
Claims (10)
1. the medical compounding sea alginate dressing containing analgesic, it is characterised in that with weight portion
Meter, described medical compounding sea alginate dressing includes following components: 50～99.9 parts of alginates, 0.1～25
Part analgesic and 0.01～15 part of surfactant.
Medical compounding sea alginate dressing containing analgesic the most according to claim 1, it is special
Levying and be, described medical compounding sea alginate dressing also includes the osmotic pressure tune of pH adjusting agent and 0.1～10 part
Joint agent, wherein, the usage amount of described pH adjusting agent is for can adjust described medical compounding sea alginate dressing
PH value to 6～11.
Medical compounding sea alginate dressing containing analgesic the most according to claim 1, it is special
Levying and be, described alginate is the salt formed by alginic acid and metal ion, wherein, described alginate
In sodium alginate, calcium alginate, alginic acid zinc, copper alginate, ferric alginate and alginic acid magnesium one
Kind；The molecular weight of described alginate is 5000～500000.
Medical compounding sea alginate dressing containing analgesic the most according to claim 1, it is special
Levy and be, described analgesic selected from lignocaine or its salt, prilocaine or its salt, bupivacaine or its
At least one in salt and ropivacaine or its salt.
Medical compounding sea alginate dressing containing analgesic the most according to claim 1, it is special
Levying and be, described medical compounding sea alginate dressing also includes 0～10 part of antibacterials, wherein, described anti-
Bacterium medicine is in gentamycin or its salt, neomycin or its salt, kanamycin or its salt and mupirocin
At least one.
Medical compounding sea alginate dressing containing analgesic the most according to claim 2, it is special
Levying and be, described surfactant is selected from tween, Myrij, Brij, sodium lauryl sulphate, dodecyl
Sodium sulfonate, poloxamer, lecithin, Polyethylene Glycol-15-hydroxy stearic acid ester, Polyethylene Glycol and emulsifying agent
At least one in OP；Described pH adjusting agent be acid or alkali, wherein, acid selected from hydrochloric acid, acetic acid, sulphuric acid,
At least one in boric acid, lactic acid, citric acid, tartaric acid and malic acid, alkali is selected from sodium hydroxide, Fructus Citri Limoniae
At least one in acid sodium and triethanolamine；Described osmotic pressure regulator is in sodium chloride, boric acid and Borax
At least one.
Medical compounding sea alginate dressing containing analgesic the most according to claim 1, it is special
Levying and be, the type of service of described medical compounding sea alginate dressing is lamellar or strip, described medical compound
Alginate dressing is applicable to acute wound, chronic wound or has the wound of transudate.
8. the medical compounding sea alginate containing analgesic as according to any one of claim 1 to 7
The preparation method of dressing, it is characterised in that described medical compounding sea alginate dressing is by following any one
The mode of kind prepares:
(1) by alginate fiber shredding, combing with or without carrying out acupuncture after cross lapping again
Or spun lacing is reinforced and is obtained dressing；
In described dressing, the solution containing analgesic or outstanding mixed liquid is sprayed into nanometer or micron droplet mode
Prepare described medical compounding sea alginate dressing；
(2) by the spinning solution throwing of alginate, silk is placed on containing analgesic through drawing-off and cleaning
The solution of thing or outstanding mixed liquid infiltrate, is dried afterwards, winds and cut into alginate fiber；
By described alginate fiber shredding, combing and with or without carry out again after cross lapping acupuncture or
Person's spun lacing is reinforced and is prepared described medical compounding sea alginate dressing；
(3) analgesic is added in the spinning solution of alginate and by gained spinning solution throwing, will
Silk through drawing-off, clean, be dried, wind and cut into alginate fiber；
By described alginate fiber shredding, combing and with or without carry out again after cross lapping acupuncture or
Person's spun lacing is reinforced and is prepared described medical compounding sea alginate dressing.
The preparation of the medical compounding sea alginate dressing containing analgesic the most according to claim 7
Method, it is characterised in that in mode (1) and mode (2), described solution containing analgesic or
Suspension also includes surfactant and, pH adjusting agent and/or osmotic pressure regulator；In mode (3)
In, described spinning solution also includes surfactant and, pH adjusting agent and/or osmotic pressure regulator.
The preparation of the medical compounding sea alginate dressing containing analgesic the most according to claim 7
Method, it is characterised in that a length of the 38 of described alginate fiber～60mm, fineness be 1.33～3.33
Dtex and fibre strength are 1.0～2.5cN/dtex；The unit are weight of described medical compounding sea alginate dressing
Amount is 50～300g/m2, preferably 100～200g/m2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610389996.9A CN105903056A (en) | 2016-06-02 | 2016-06-02 | Medical composite alginate dressing containing analgesic drug and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610389996.9A CN105903056A (en) | 2016-06-02 | 2016-06-02 | Medical composite alginate dressing containing analgesic drug and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105903056A true CN105903056A (en) | 2016-08-31 |
Family
ID=56743212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610389996.9A Pending CN105903056A (en) | 2016-06-02 | 2016-06-02 | Medical composite alginate dressing containing analgesic drug and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105903056A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108744016A (en) * | 2018-07-27 | 2018-11-06 | 望江汇通纺织有限公司 | A kind of preparation method of the medical adhesive-bonded fabric dressing of moisture absorption anti-inflammatory |
| WO2019113623A1 (en) * | 2017-12-11 | 2019-06-20 | Animal Ethics Pty Ltd | Wound dressing |
| CN115025070A (en) * | 2022-05-30 | 2022-09-09 | 浙江大学 | Rapid self-filming anti-infection analgesic spray and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1328475A (en) * | 1998-11-24 | 2001-12-26 | 强生消费者公司 | Coating useful as dispenser of active ingredient no dressings and bandages |
| CN101049514A (en) * | 2007-05-11 | 2007-10-10 | 东华大学 | Antibacterial anti hemorrhagic antalgic dressing of medical use, preparation and application |
| CN102552966A (en) * | 2012-01-31 | 2012-07-11 | 青岛明药堂医药科技开发有限公司 | Alginate antibacterial dressing and its preparation method |
-
2016
- 2016-06-02 CN CN201610389996.9A patent/CN105903056A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1328475A (en) * | 1998-11-24 | 2001-12-26 | 强生消费者公司 | Coating useful as dispenser of active ingredient no dressings and bandages |
| CN101049514A (en) * | 2007-05-11 | 2007-10-10 | 东华大学 | Antibacterial anti hemorrhagic antalgic dressing of medical use, preparation and application |
| CN102552966A (en) * | 2012-01-31 | 2012-07-11 | 青岛明药堂医药科技开发有限公司 | Alginate antibacterial dressing and its preparation method |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019113623A1 (en) * | 2017-12-11 | 2019-06-20 | Animal Ethics Pty Ltd | Wound dressing |
| EP3723819A4 (en) * | 2017-12-11 | 2021-09-29 | Animal Ethics Pty Ltd | WOUND DRESSING |
| US11338055B2 (en) | 2017-12-11 | 2022-05-24 | Animal Ethics Pty Ltd | Wound dressing |
| AU2018384069B2 (en) * | 2017-12-11 | 2022-12-08 | Animal Ethics Pty Ltd | Wound dressing |
| CN108744016A (en) * | 2018-07-27 | 2018-11-06 | 望江汇通纺织有限公司 | A kind of preparation method of the medical adhesive-bonded fabric dressing of moisture absorption anti-inflammatory |
| CN115025070A (en) * | 2022-05-30 | 2022-09-09 | 浙江大学 | Rapid self-filming anti-infection analgesic spray and preparation method and application thereof |
| CN115025070B (en) * | 2022-05-30 | 2024-02-09 | 浙江大学 | Quick self-film-forming anti-infection analgesic spray and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105999362A (en) | Medical composite alginate dressing containing antibacterial drug and preparation method thereof | |
| US7799965B2 (en) | Wound dressings with anti-microbial and zinc-containing agents | |
| CA2352296C (en) | Collagen hemostatic fibers | |
| US20090012440A1 (en) | Wound dressings | |
| JP2020000857A (en) | Antiseptic wound dressing | |
| CN105854069A (en) | Alginate dressing containing wound-healing promoting medicine and preparing method thereof | |
| CN107693835A (en) | A kind of polyvinyl alcohol/collagen/n-trimethyl chitosan chloride electrospun composite fibers film and preparation method thereof | |
| CN113413267A (en) | High-absorptivity wound dressing | |
| CN109248333B (en) | Medical dressing for resisting bacteria and promoting wound healing and preparation method and application thereof | |
| JP6212552B2 (en) | Dressing material that releases active ingredients continuously | |
| CN103768650A (en) | Wound regenerating and repairing bandage and manufacture method thereof | |
| CN103263694A (en) | Collagen-based dura and preparation method thereof | |
| CN105903056A (en) | Medical composite alginate dressing containing analgesic drug and preparation method thereof | |
| CN106377791A (en) | Bamboo alginate functional dressing and preparation method thereof | |
| CN101678036A (en) | Novel active substance in cicatrisation and use thereof | |
| CN109731121A (en) | A kind of preparation method of cellulose and chitosan composite dressing containing mesoporous silica | |
| MX2008000969A (en) | Biomaterials based on carboxymethylcellulose salified with zinc associated with hyaluronic acid derivatives. | |
| CN102552964A (en) | Nano silver chitosan composite antibacterial composition, adhesive bandage and preparation method of adhesive bandage | |
| CN109395154A (en) | A kind of high porosity carries the preparation method of medicine wound dressing | |
| CN104906029A (en) | A kind of nasal cavity preparation and its preparation method and application | |
| CN105640705A (en) | Composite functional surgical dressing | |
| US20060120993A1 (en) | Treatment of lesions of the soft tissues | |
| CN108939136A (en) | A kind of dressing and preparation method thereof for nose filling hemostasis | |
| EP1005844B1 (en) | Bandage cloth having an extended therapeutic action | |
| CN108042839A (en) | A kind of chitosan complexes bandage and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160831 |